IP Library › Granted Patent US 9,897,606
Granted Patent B2
US 9,897,606 · App. 15/219,976 · Granted Feb 20, 2018

Reagents and methods for detecting influenza

Inventors: Xuguang Li (Winnipeg, CA); Runtao He (Winnipeg, CA); Gary Van Domselaar (Winnipeg, CA)
G01N33/56983C12N9/2402C12Y302/01018G01N2333/924
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,897,606
App. No.
15/219,976
Granted
Feb 20, 2018
Kind
B2
Abstract

Two universally conserved sequences from influenza type A neuraminidases were identified by large scale sequence analysis then chemically modified and conjugated to carrier proteins to generate mono-specific and monoclonal antibodies. The two antibodies, one targeting the N-terminus of the type A neuraminidase and the other sequence close to enzymatic active site, were capable of binding to all 9 subtypes of neuraminidase while demonstrating remarkable specificity against the viral neuraminidase sequences since no cross-reactivity against allantoic proteins was observed. Quantitative analyses of NA using slot blot suggest that the antibodies can be used for NA antigen quantitation in vaccines. These represent the first time the antibody-based immunoassay can be used for NA quantitative determination.

Claims (7)

1. A composition comprising an influenza neuramidase peptide consisting of the amino acid sequence as set forth in SEQ ID No. 1 or SEQ ID No. 2 attached to the first end of a spacer, a tripeptide linker KKC connected to the second end of the spacer and a carrier protein connected to the tripeptide linker.

2. The composition according to claim 1 wherein the spacer is selected from the group consisting of amino acids, peptides, phosphoramidite, ε-aminohexanoic acid and 6-aminocaproic acid.

3. The composition according to claim 1 wherein the carrier protein is selected from the group consisting of keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA), rabbit serum albumin (RSA), ovalbumin (OVA), thyroglobulin (THY) and human gamma globulin (HGG).

4. The composition according to claim 1 wherein the spacer is 6-aminocaproic acid.

5. A composition consisting of an influenza neuramidase peptide consisting of the amino acid sequence as set forth in SEQ ID No. 1 or SEQ ID No. 2 attached to the first end of a spacer, a tripeptide linker KKC connected to the second end of the spacer, and a carrier protein connected to the tripeptide linker.

6. The composition according to claim 5 wherein the carrier protein is selected from the group consisting of keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA), rabbit serum albumin (RSA), ovalbumin (OVA), thyroglobulin (THY) and human gamma globulin (HGG).

7. The composition according to claim 5 wherein the spacer is 6-aminocaproic acid.

Continuity (4)
Division 14556415 · Dec 1, 2014
Division 13322459
Provisional Application 61182920 · Jun 1, 2009
Related Publication 20170131277A1 · May 11, 2017